Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine
National Institute for Clinical Excellence
Record ID 32003000011
English
Authors' objectives:
To provide guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine.
Authors' recommendations:
Guidance: 1.1 Insulin glargine is recommended as a treatment option for people with type 1 diabetes.
1.2 Insulin glargine is not recommended for routine use for people with type 2 diabetes who require insulin therapy. Insulin glargine treatment should be considered only for those people with type 2 diabetes who require insulin therapy and who fall into one of the following categories. - Those who require assistance from a carer or healthcare professional to administer their insulin injections. - Those whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemic episodes. - Those who would otherwise need twice-daily basal insulin injections in combination with oral antidiabetic drugs.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=43424
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Diabetes Mellitus
- Insulin
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.